Lantheus Holdings's Total Assets for the quarter that ended in Mar. 2026 was $2,347 Mil.
During the past 12 months, Lantheus Holdings's average Total Assets Growth Rate was 65.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 27.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 16.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 24.10% per year.
During the past 13 years, Lantheus Holdings's highest 3-Year average Total Assets Growth Rate was 42.50%. The lowest was -9.80%. And the median was 15.20%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Lantheus Holdings's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Lantheus Holdings Total Assets Related Terms
Lantheus Holdings Total Assets Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Lantheus Holdings's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Total Assets of $2,347 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Lantheus Holdings and its competitors.
Is Lantheus Holdings' Total Assets too high?
Lantheus Holdings' current Total Assets is $2,347 Mil. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Total Assets compare to LQDA and HIMS?
Lantheus Holdings' Total Assets of $2,347 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Lantheus Holdings and its competitors. Lantheus Holdings's current Total Assets is $2,347 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.85, compared to a current price of $108.89 — trading 19.9% above its estimated fair value. The current Total Assets is $2,347 Mil. Lantheus Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Total Assets is $2,347 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $108.89 is trading 19.9% above its estimated GF Value™ of $90.85.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
Total Assets: $2,347 Mil
GF Value™: $90.85 vs. price of $108.89 (19.9% above fair value)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score
Get the complete analysis for LNTH
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
